Prime Medicine (PRME) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

PRME Stock Forecast


Prime Medicine stock forecast is as follows: an average price target of $17.25 (represents a 335.61% upside from PRME’s last price of $3.96) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

PRME Price Target


The average price target for Prime Medicine (PRME) is $17.25 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $23.00 to $12.00. This represents a potential 335.61% upside from PRME's last price of $3.96.

PRME Analyst Ratings


Buy

According to 6 Wall Street analysts, Prime Medicine's rating consensus is 'Buy'. The analyst rating breakdown for PRME stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Prime Medicine Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 07, 2024Maury RaycroftJefferies$15.00$5.40177.78%278.79%
Apr 02, 2024David NierengartenWedbush$12.00$6.3289.87%203.03%
Oct 09, 2023Kostas BiliourisBMO Capital$19.00$8.75117.14%379.80%
Nov 14, 2022-Morgan Stanley$23.00$21.128.90%480.81%
Row per page
Go to

The latest Prime Medicine stock forecast, released on May 07, 2024 by Maury Raycroft from Jefferies, set a price target of $15.00, which represents a 177.78% increase from the stock price at the time of the forecast ($5.40), and a 278.79% increase from PRME last price ($3.96).

Prime Medicine Price Target by Period


1M3M12M
# Anlaysts--2
Avg Price Target--$13.50
Last Closing Price$3.96$3.96$3.96
Upside/Downside-100.00%-100.00%240.91%

In the current month, the average price target of Prime Medicine stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Prime Medicine's last price of $3.96. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 01, 2024BMO CapitalOutperformOutperformHold
May 20, 2024H.C. Wainwright-BuyInitialise
May 15, 2024Citigroup-BuyUpgrade
Apr 08, 2024Cowen & Co.-BuyInitialise
Apr 03, 2024WedbushBuyOutperformInitialise
Apr 02, 2024Wedbush-BuyInitialise
Nov 14, 2022Morgan Stanley-Equal-WeightInitialise
Row per page
Go to

Prime Medicine's last stock rating was published by BMO Capital on Oct 01, 2024. The company gave PRME a "Outperform" rating, the same as its previous rate.

Prime Medicine Financial Forecast


Prime Medicine Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23
Revenue----------
Avg Forecast$25.53M$27.44M$29.48M$31.68M$6.63M$7.09M$1.63M$1.92M$5.71M$1.67M
High Forecast$25.53M$27.44M$29.48M$31.68M$6.63M$7.09M$1.63M$1.92M$5.71M$1.67M
Low Forecast$25.53M$27.44M$29.48M$31.68M$6.63M$7.09M$1.63M$1.92M$5.71M$1.67M
# Analysts3333454363
Surprise %----------

Prime Medicine's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PRME's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Prime Medicine EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23
# Analysts3333454363
EBITDA---------$-51.46M
Avg Forecast$15.32M$16.46M$17.69M$19.01M$3.98M$4.25M$978.00K$1.15M$3.43M$1.00M
High Forecast$15.32M$16.46M$17.69M$19.01M$3.98M$4.25M$978.00K$1.15M$3.43M$1.00M
Low Forecast$15.32M$16.46M$17.69M$19.01M$3.98M$4.25M$978.00K$1.15M$3.43M$1.00M
Surprise %----------51.46%

undefined analysts predict PRME's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Prime Medicine's previous annual EBITDA (undefined) of $NaN.

Prime Medicine Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23
# Analysts3333454363
Net Income---------$-50.71M
Avg Forecast$-39.69M$-39.07M$-45.68M$-47.42M$-45.72M$-45.93M$-46.46M$-54.22M$-66.27M$-51.75M
High Forecast$-39.69M$-39.07M$-45.68M$-47.42M$-45.72M$-37.38M$-46.46M$-54.22M$-60.74M$-51.75M
Low Forecast$-39.69M$-39.07M$-45.68M$-47.42M$-45.72M$-50.20M$-46.46M$-54.22M$-73.17M$-51.75M
Surprise %---------0.98%

Prime Medicine's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PRME's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Prime Medicine SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23
# Analysts3333454363
SG&A---------$10.49M
Avg Forecast$23.53M$25.28M$27.17M$29.19M$6.11M$6.53M$1.50M$1.77M$5.27M$1.54M
High Forecast$23.53M$25.28M$27.17M$29.19M$6.11M$6.53M$1.50M$1.77M$5.27M$1.54M
Low Forecast$23.53M$25.28M$27.17M$29.19M$6.11M$6.53M$1.50M$1.77M$5.26M$1.54M
Surprise %---------6.83%

Prime Medicine's average Quarter SG&A projection for Dec 23 is $5.27M, based on 6 Wall Street analysts, with a range of $5.26M to $5.27M. The forecast indicates a -49.82% fall compared to PRME last annual SG&A of $10.49M (Sep 23).

Prime Medicine EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23
# Analysts3333454363
EPS---------$-0.55
Avg Forecast$-0.33$-0.33$-0.38$-0.40$-0.38$-0.39$-0.39$-0.45$-0.56$-0.43
High Forecast$-0.33$-0.33$-0.38$-0.40$-0.38$-0.31$-0.39$-0.45$-0.51$-0.43
Low Forecast$-0.33$-0.33$-0.38$-0.40$-0.38$-0.42$-0.39$-0.45$-0.61$-0.43
Surprise %---------1.27%

According to undefined Wall Street analysts, Prime Medicine's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PRME previous annual EPS of $NaN (undefined).

Prime Medicine Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
IPSCCentury Therapeutics$1.26$20.001487.30%Buy
NTLAIntellia Therapeutics$15.14$118.84684.94%Buy
LIFEaTyr Pharma$1.90$11.00478.95%Buy
EDITEditas Medicine$2.88$13.50368.75%Buy
PRMEPrime Medicine$3.96$17.25335.61%Buy
VERVVerve Therapeutics$6.05$21.50255.37%Buy
RLAYRelay Therapeutics$5.85$19.40231.62%Buy
SANASana Bio$3.76$12.00219.15%Buy
BEAMBeam Therapeutics$24.36$64.20163.55%Buy
CRSPCRISPR Therapeutics$50.59$109.58116.60%Buy
RPRXRoyalty Pharma$27.20$43.3359.30%Buy
CRBUCaribou Biosciences$2.34$3.0028.21%Buy
BPMCBlueprint Medicines$91.88$109.7119.41%Buy
RPHMReneo Pharmaceuticals$18.20$18.00-1.10%Buy
DNAGinkgo Bioworks$7.63$7.34-3.80%Buy

PRME Forecast FAQ


Yes, according to 6 Wall Street analysts, Prime Medicine (PRME) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 83.33% of PRME's total ratings.

Prime Medicine (PRME) average price target is $17.25 with a range of $12 to $23, implying a 335.61% from its last price of $3.96. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for PRME stock, the company can go up by 335.61% (from the last price of $3.96 to the average price target of $17.25), up by 480.81% based on the highest stock price target, and up by 203.03% based on the lowest stock price target.

PRME's average twelve months analyst stock price target of $17.25 supports the claim that Prime Medicine can reach $6 in the near future.

Prime Medicine's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $17.27M (high $17.27M, low $17.27M), average EBITDA is $10.36M (high $10.36M, low $10.36M), average net income is $-192M (high $-184M, low $-197M), average SG&A $15.91M (high $15.91M, low $15.91M), and average EPS is $-1.614 (high $-1.542, low $-1.649). PRME's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $114.14M (high $114.14M, low $114.14M), average EBITDA is $68.48M (high $68.48M, low $68.48M), average net income is $-172M (high $-172M, low $-172M), average SG&A $105.17M (high $105.17M, low $105.17M), and average EPS is $-1.442 (high $-1.442, low $-1.442).